The combination of ribociclib and endocrine therapy demonstrates consistent efficacy and a manageable safety profile across different age groups in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. This conclusion stems from pooled analyses of the MONALEESA-2, -3, and -7 trials presented at the 2023 San Antonio Breast […]